A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
- Registry ID
- CO46274
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2026-01-30
- Last update
- 2025-11-24
Conditions
Related clinical trials
- 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- A PHASE IB/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY
EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF
GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN
COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN
PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC
ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6
INHIBITOR
- A PHASE 3 OPEN-LABEL RANDOMIZED STUDY ASSESSING THE EFFICACY AND
SAFETY OF RLY-2608 + FULVESTRANT VERSUS CAPIVASERTIB + FULVESTRANT AS TREATMENT FOR
PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR
2 NEGATIVE (HR+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE OR PROGRESSION ON OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR
- A PHASE I/II, MULTI-SITE, OPEN-LABEL, TWO-PART TRIAL TO EVALUATE THE EFFICACY, SAFETY,
AND PHARMACOKINETICS OF BNT323 IN COMBINATION WITH BNT327 IN PARTICIPANTS
WITH ADVANCED BREAST CANCER
- HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING
STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB
DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY
ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER
View on source registry